HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist/mGluR8 agonist.

Abstract
An involvement of glutamatergic transmission in schizophrenia has been postulated for several years. According to that view, hypofunction of NMDA receptors and a compensatory increase in glutamate release which overstimulates non-NMDA receptors contributes to psychotic symptoms. Therefore, potential antipsychotic drugs are searched for among compounds which block AMPA receptors and inhibit glutamate release. (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG] is a mixed antagonist of AMPA receptors and agonist of an autoreceptor, i.e. metabotropic glutamate receptor 8. The aim of the study was to look for putative antipsychotic properties of (R,S)-3,4-DCPG in the model of locomotor stimulation induced by amphetamine or phencyclidine in mice. Moreover, a risk of extrapyramidal side-effects induced by this compound was examined, as capability to induce catalepsy in the bar test and to increase the proenkephalin mRNA expression, measured autoradiographically in striatal slices by in situ hybridization. (R,S)-3,4-DCPG (80 mg/kg i.p.) decreased the amphetamine (2.5 mg/kg s.c.)-but not phencyclidine (3 mg/kg s.c.)-induced hyperactivity. That dose of (R,S)-3,4-DCPG did not decrease the spontaneous locomotor activity of mice. However, a dose of 100 mg/kg ip of that compound evoked catalepsy and enhanced the catalepsy and striatal proenkephalin mRNA expression induced by haloperidol (1-2 mg/kg i.p.). The study seems to suggest that (R,S)-3,4-DCPG may possess antipsychotic properties at doses close to those evoking extrapyramidal side-effects which speaks for its rather typical than atypical neuroleptic profile.
AuthorsKrystyna Ossowska, Małgorzata Pietraszek, Jadwiga Wardas, Stanisław Wolfarth
JournalPolish journal of pharmacology (Pol J Pharmacol) 2004 May-Jun Vol. 56 Issue 3 Pg. 295-304 ISSN: 1230-6002 [Print] Poland
PMID15215559 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 3,4-dicarboxyphenylglycine
  • Antipsychotic Agents
  • Benzoates
  • Central Nervous System Stimulants
  • Receptors, AMPA
  • Amphetamine
  • Phencyclidine
  • Glycine
Topics
  • Amphetamine (pharmacology)
  • Animals
  • Antipsychotic Agents (adverse effects, pharmacology)
  • Basal Ganglia Diseases (chemically induced)
  • Benzoates (adverse effects, pharmacology)
  • Catalepsy (chemically induced)
  • Central Nervous System Stimulants (pharmacology)
  • Drug Interactions
  • Glycine (adverse effects, analogs & derivatives, pharmacology)
  • Male
  • Mice
  • Motor Activity (drug effects)
  • Phencyclidine (pharmacology)
  • Receptors, AMPA (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: